Ocelot Bio, Inc.
🇺🇸United States
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
Phase 2
Completed
- Conditions
- AscitesAcute Kidney InjuryCirrhosisHepatorenal Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Ocelot Bio, Inc
- Target Recruit Count
- 47
- Registration Number
- NCT05309200
- Locations
- 🇺🇸
Piedmont Atlanta Hospital, Atlanta, Georgia, United States
🇺🇸University of Missouri, Columbia, Missouri, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada